To include your compound in the COVID-19 Resource Center, submit it here.

Sanofi sees first fruit of renewed oncology commitment with Sarclisa approval

Sanofi solidifies comeback with first FDA cancer approval in more than a decade

Sarclisa isatuximab will be the first oncology drug Sanofi launches in more than a decade, its approval Monday marking the pharma’s first cancer win after its re-entry into the space. The company’s next step is finding a home for the anti-CD38 mAb in a crowded multiple myeloma market.

FDA approved the Sanofi (Euronext:SAN; NASDAQ:SNY) drug in combination with pomalidomide and dexamethasone (pom-dex) to treat relapsed

Read the full 655 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers